drugset / Trial / NCT00723502

Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients

NCT00723502

Phase 2 Completed 30 enrolled MerLion Pharmaceuticals GmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole. The secondary objective is to evaluate and compare the safety and tolerability of multiple oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole.

Timeline

Start
2008-09
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg Oral
Subject Esomeprazole Small molecule 40 mg Oral
Subject Finafloxacin Small molecule 400 mg Oral